IDEAYA Biosciences priced a $300 million public offering of common stock and pre-funded warrants at $27.00 per share. Shares fell 8.5% in after-hours trading as the market priced in dilution. The capital raise funds the company's precision oncology pipeline including lead candidate IDE397.
IDEAYA Biosciences Inc. priced a $300 million underwritten public offering of common stock and pre-funded warrants Monday, sending shares down 8.5% in after-hours trading as investors priced in dilution from the capital raise.
The South San Francisco-based precision oncology company is selling 5,555,556 shares at $27.00 each and 5,555,576 pre-funded warrants at $26.9999 per warrant, according to a statement. The pre-funded warrants, which allow holders to purchase one share at $0.0001 each, are being offered to certain investors in lieu of common stock. Underwriters have a 30-day option to purchase up to an additional 1,666,669 shares, or about $45 million.
"The net proceeds will be used for working capital and other general corporate purposes, including to fund our research and development activities," the company said in its prospectus. IDEAYA had not yet disclosed its cash position following the raise, though its most recent quarterly filing showed sufficient runway to fund operations into 2027.
J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank and Cantor are acting as joint book-running managers, with Wedbush PacGrow serving as lead manager. The offering is expected to close June 10, subject to customary conditions.
IDEAYA specializes in precision oncology, developing small-molecule drugs targeting synthetic lethality pathways and antibody-drug conjugates for solid tumors with specific genetic drivers. Synthetic lethality exploits genetic vulnerabilities in cancer cells — when a tumor has a mutation in one gene, inhibiting a second gene kills the cancer while sparing healthy tissue. IDEAYA's lead candidate, IDE397, a MAT2A inhibitor, is in Phase 2 trials for MTAP-deleted solid tumors, a genetic alteration found in about 15% of all cancers including non-small cell lung cancer and pancreatic cancer. The company also has early-stage programs targeting PARG, WRN and Pol Theta, each addressing distinct patient populations defined by specific biomarkers.
The $300 million raise strengthens IDEAYA's balance sheet as it moves IDE397 toward potential registration trials and expands its ADC pipeline. Biotech companies at this stage typically require substantial capital to fund late-stage clinical development, and the offering provides IDEAYA with financial flexibility through multiple data readouts expected over the next 12 to 18 months.
Shares closed Monday at $31.48, up 11% in regular trading, before falling to $28.81 after hours. The stock has declined 8.9% year to date, giving IDEAYA a market capitalization of roughly $2.6 billion at the closing price. The after-hours decline suggests the market views the offering as near-term dilutive, though the capital infusion reduces financing risk for the company's clinical programs.
This article is for informational purposes only and does not constitute investment advice.
